Published in Clin Med Res on November 01, 2005
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity (2015) 1.80
Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res (2008) 1.25
Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res (2011) 1.24
Current status of mucins in the diagnosis and therapy of cancer. Biofactors (2009) 1.17
Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci (2007) 1.02
Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol (2012) 0.93
Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens. Clin Vaccine Immunol (2006) 0.90
Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget (2015) 0.86
Lung cancer vaccines. Cancer J (2011) 0.82
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. Biologics (2008) 0.79
Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg (2011) 0.78
Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. J Thorac Dis (2016) 0.75
Surface properties and cell adhesion onto allylamine-plasma and amine-plasma coated glass coverslips. J Mater Sci Mater Med (2011) 0.75
Gene set selection via LASSO penalized regression (SLPR). Nucleic Acids Res (2017) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A (2004) 2.58
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci (2003) 1.78
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother (2000) 1.35
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 1.33
Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol (1999) 1.29
Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer (2001) 1.19
Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol (2004) 1.18
Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg (2004) 1.17
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res (2004) 1.13
Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol (1978) 1.12
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res (2004) 1.09
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer (2005) 1.09
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res (1999) 1.08
B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med (1996) 1.03
Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses. Immunol Lett (2000) 1.00
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer (2004) 0.99
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol (1995) 0.98
Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther (2003) 0.98
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol (2002) 0.96
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) (1992) 0.96
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 0.96
A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res (2000) 0.94
Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol (1995) 0.92
Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol (2003) 0.91
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer (1992) 0.89
Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer (1979) 0.88
Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res (2000) 0.87
Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol (2004) 0.87
Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother (1993) 0.87
Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother (2001) 0.86
Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol (2001) 0.86
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res (1999) 0.85
Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol (1996) 0.85
Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res (1986) 0.84
Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. Cancer (1979) 0.83
Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res (1979) 0.83
Translational development of active immunotherapy for hematologic malignancies. Semin Oncol (2003) 0.82
BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Neoplasma (1982) 0.81
Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep (1978) 0.81
Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol (1985) 0.80
Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol Lett (2000) 0.80
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs (2003) 0.80
B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol (2000) 0.78
Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol (1997) 0.78
Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Curr Opin Mol Ther (2002) 0.76
Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunol Immunother (2003) 0.76
Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int J Cancer (1998) 0.76
Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts. Hiroshima J Med Sci (2000) 0.76
Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med (2008) 1.89
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy (2011) 1.74
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest (2010) 1.50
IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J Immunol (2012) 1.21
The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother (2011) 1.06
Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. J Immunother (2008) 1.06
Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J Immunol (2007) 1.06
CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol (2004) 1.05
CD30: an important new target in hematologic malignancies. Leuk Lymphoma (2011) 1.05
Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity (2003) 0.98
B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother (2012) 0.98
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 0.96
Ability of prospective assessment of personality profiles to predict the practice specialty of medical students. Proc (Bayl Univ Med Cent) (2007) 0.95
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res (2009) 0.95
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
B cell regulation of anti-tumor immune response. Immunol Res (2013) 0.91
Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J Immunol (2013) 0.91
Effects of obesity and subsequent weight reduction on left ventricular function. Cardiol Rev (2010) 0.91
APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol (2008) 0.90
A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology (2007) 0.90
CD30: from basic research to cancer therapy. Immunol Res (2013) 0.90
Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation (2012) 0.89
A novel role of CD30/CD30 ligand signaling in the generation of long-lived memory CD8+ T cells. J Immunol (2005) 0.88
CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol (2010) 0.88
Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritis. J Rheumatol (2003) 0.88
Secreted heat shock protein gp96-Ig: an innovative vaccine approach. Am J Reprod Immunol (2008) 0.88
Inhibition of intracellular bacterial replication in fibroblasts is dependent on the perforin-like protein (perforin-2) encoded by macrophage-expressed gene 1. J Innate Immun (2012) 0.88
Immunobiology of TNFSF15 and TNFRSF25. Immunol Res (2013) 0.88
The role of TNFRSF25:TNFSF15 in disease… and health? Adv Exp Med Biol (2011) 0.87
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol (2010) 0.87
TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. J Virol (2012) 0.87
A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol (2008) 0.86
Heat shock protein-based cancer vaccines. Hematol Oncol Clin North Am (2006) 0.86
Cloning, expression, and functional characterization of TL1A-Ig. J Immunol (2013) 0.85
Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res (2007) 0.84
T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J Immunol (2012) 0.84
CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J Immunol (2010) 0.84
Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine (2011) 0.84
Killing machines: three pore-forming proteins of the immune system. Immunol Res (2013) 0.84
Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther (2003) 0.83
Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. J Immunother (2015) 0.83
Present and future of lung cancer vaccines. Expert Opin Emerg Drugs (2006) 0.83
The impact of weight loss on cardiac structure and function in obese patients. Obes Surg (2008) 0.82
The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. Immunol Res (2013) 0.82
Progesterone induced blocking factor (PIBF) mediates progesterone induced suppression of decidual lymphocyte cytotoxicity. Am J Reprod Immunol (2002) 0.82
IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytes. Am J Reprod Immunol (2002) 0.82
Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation (2004) 0.82
Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunol Res (2013) 0.82
Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis. J Virol (2003) 0.81
Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunol Res (2013) 0.80
CD30 is required for activation of a unique subset of interleukin-17A-producing γδ T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection. Infect Immun (2013) 0.80
The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice. Eur J Immunol (2011) 0.79
Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am J Reprod Immunol (2002) 0.78
CD30 supports lung inflammation. Int Immunol (2007) 0.78
Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice. Blood (2014) 0.78
Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. Antiviral Res (2003) 0.77
Short-term cytolytic mediators' expression in decidual lymphocytes is enhanced by interleukin-15. Am J Reprod Immunol (2006) 0.76
TNF superfamily member 13, APRIL, inhibits allergic lung inflammation. Eur J Immunol (2010) 0.76
Effect of comorbidities and medications on left ventricular mass regression after bariatric surgery. J Clin Hypertens (Greenwich) (2010) 0.76
CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. Dig Dis Sci (2012) 0.76
Regulation of lymphocyte clustering by CD30-mediated ICAM-1 up-regulation. Cell Immunol (2002) 0.76
MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections. JCI Insight (2017) 0.75
Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev Anticancer Ther (2005) 0.75
Factors associated with adverse long-term outcomes in ischemic stroke: development of a prediction model and its validation. Int J Stroke (2014) 0.75